Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ian Flinn

Hematology & Oncology Nashville, TN Medical Doctor

NPI 1417990367 CMS profile 336273

250 25Th Ave N, Ste 412, Nashville, TN 37203

Open in the dashboard

General payments

$94,358

374 records reported · program years 2019–2025

Research payments

$62,536

Paid to them · 27 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$41,064,790 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ian Flinn of Nashville, TN is reported in the CMS Open Payments database as having received $94,358 across 374 general payments and $62,536 in research payments paid to them. Separately, studies naming them as principal investigator received $41,064,790 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,068 70
2025 Research $5,507 7
2024 General $22,118 44
2024 Research $10,085 7
2023 General $5,402 41
2023 Research $3,011 1
2022 General $8,584 16
2022 Research $20,658 2
2021 General $11,450 4
2021 Research $16 1
2020 General $11,497 28
2020 Research $6,899 4
2019 General $26,239 171
2019 Research $16,359 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Flinn
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Ian Flinn were reported at $9,068. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Ian Flinn Hematology & Oncology median Middle half National median
2019 $26,239 $529 $121–$2,516 $163
2020 $11,497 $339 $82–$2,213 $114
2021 $11,450 $263 $49–$1,965 $132
2022 $8,584 $416 $103–$2,395 $149
2023 $5,402 $542 $125–$2,646 $160
2024 $22,118 $692 $141–$3,008 $164
2025 $9,068 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kite Pharma, Inc. $22,577 21 payments
  2. AbbVie, Inc. $20,703 37 payments
  3. BeiGene USA, Inc. $9,646 14 payments
  4. Genentech, Inc. $9,360 4 payments
  5. F. Hoffmann-La Roche AG $5,169 15 payments
  6. Genzyme Corporation $5,104 7 payments
  7. Janssen Biotech, Inc. $3,302 10 payments
  8. Genentech USA, Inc. $3,239 16 payments
  9. Genmab U.S., Inc. $3,219 7 payments
  10. Gilead Sciences, Inc. $3,193 6 payments
  11. Other $8,846 237 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $81,435 40 payments
  2. Food and Beverage $8,345 313 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,849 14 payments
  4. Travel and Lodging $702 5 payments
  5. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. BRUKINSA $11,562 18 payments
  2. Yescarta $9,853 9 payments
  3. EPKINLY $8,171 13 payments
  4. VENCLEXTA Oncology $8,171 12 payments
  5. Non-Covered Product $7,692 12 payments
  6. Venclexta Virology $4,756 12 payments
  7. VENCLEXTA BioOncology $3,532 12 payments
  8. IMBRUVICA $3,275 9 payments
  9. Tecartus $3,020 1 payment
  10. POLIVY $2,916 5 payments
  11. Other $11,498 298 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $24,542 17 payments
  2. Eli Lilly and Company $20,658 2 payments
  3. Celgene Corporation $14,487 3 payments
  4. Acerta Pharma LLC $1,764 1 payment
  5. Novartis Pharmaceuticals Corporation $961 2 payments
  6. Kite Pharma, Inc. $109 1 payment
  7. TG Therapeutics, Inc. $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

804

Median for Hematology-Oncology: 604

Drug cost

$7,349,217

Median for Hematology-Oncology: $1,306,514

Branded share of claims

72.5%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calquence Acalabrutinib Maleate Brand 134 $1,921,259
Brukinsa Zanubrutinib Brand 116 $1,623,396
Venclexta Venetoclax Brand 94 $972,781
Imbruvica Ibrutinib Brand 56 $918,186
Jaypirca Pirtobrutinib Brand 29 $606,399
Pomalyst Pomalidomide Brand 26 $546,517
Tasigna Nilotinib Hcl Brand 13 $254,906
Revlimid Lenalidomide Brand 15 $243,948
Jakafi Ruxolitinib Phosphate Brand 11 $133,664
Sprycel Dasatinib Brand 11 $111,926

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$1,229,501

Of which drugs: $992,711

Medicare patients

255

Average age 73

Services billed

43,925

126 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Diabetes 27%
Ischemic heart disease 26%
Chronic kidney disease 25%
Atrial fibrillation 23%
Heart failure 18%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 14 3,040 $110,298
Infusion, normal saline solution , 1000 cc J7030 Office 13 32 $67
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 518 $47

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EPKINLY
  • AbbVie, Inc. $3,518
  • Genmab U.S., Inc. $3,025
$6,542 — —
BRUKINSA
  • BeiGene USA, Inc. $6,513
$6,513 116 —
LUNSUMIO
  • Genentech USA, Inc. $950
$950 — —
POLIVY
  • Genentech USA, Inc. $950
$950 — —
Columvi
  • Genentech USA, Inc. $950
$950 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

401 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record